Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

@article{Moya2010ActivityOA,
  title={Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.},
  author={Bartolome Moya and Laura Zamorano and Carlos Juan and Jos{\'e} Luis F{\'i}rvida P{\'e}rez and Yigong Ge and Antonio Oliver},
  journal={Antimicrobial agents and chemotherapy},
  year={2010},
  volume={54 3},
  pages={1213-7}
}
CXA-101, previously designated FR264205, is a new antipseudomonal cephalosporin. We evaluated the activity of CXA-101 against a highly challenging collection of beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit (ICU) patients. The in vitro mutants investigated included strains with multiple combinations of mutations leading to several degrees of AmpC overexpression (ampD, ampDh2, ampDh3, and dacB [PBP4]) and porin… CONTINUE READING